Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

NCT01926587 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Interventions

DRUG: oral rigosertib
DRUG: Azacitidine

Sponsor

Traws Pharma, Inc.